Digital Psychotherapeutics Market Size By Solution (Monotherapy, Combination), By Application (Prevention, Management, Treatment), By Indication (Phobias and Anxiety, Psychotic), By Business Model (Direct-to-patients, B2B) – Global Forecast to 2032

The competitive landscape of the digital psychotherapeutics industry includes prominent firms, such as Novartis AG, Pear Therapeutics, SilverCloud Health, Woebot Health, Starling Minds, SwissDT, AbleTo, Inc., Spring Care, Inc, Meru, and Ginger.

The combination therapy segment generated USD 836 million in 2022 and is estimated to witness high demand through 2032 attributed to its improved treatment efficacy.

North America digital psychotherapeutics industry amassed USD 700.3 million in revenue in 2022 and is set to witness robust growth through 2032 with the increasing mental health awareness and the growing recognition of the importance of mental well-being in the region.

Digital psychotherapeutics industry reached around USD 1.2 billion in revenue in 2022 and is projected to be worth USD 16.9 billion by 2032 owing to the rising prevalence of psychological disorders and the surging demand for accessible and effective treatment choices.